Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression
- PMID: 29727073
- DOI: 10.4088/JCP.17m11634
Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression
Abstract
Objective: The present study examined the efficacy, safety, and durability of repeated ketamine infusions for the treatment of comorbid posttraumatic stress disorder (PTSD) and treatment-resistant depression (TRD) in a sample of veterans.
Methods: Individuals with comorbid DSM-5-defined PTSD and DSM-IV-defined major depressive disorder (N = 15) received 6 intravenous ketamine infusions (0.5 mg/kg) on a Monday-Wednesday-Friday schedule over a 12-day period from May 2015 to June 2016. Data from outcome measures were collected before and 24 hours after each infusion and weekly for 8 weeks following the final infusion.
Results: Continuous measures of symptom change were significant for both disorders and were associated with large effect sizes (mean decrease in PTSD Checklist for DSM-5 score = 33.3 points [95% CI, 23.0-43.5 points], P < .0005, sample size-adjusted Cohen d [d'] = 2.17; mean decrease in Montgomery-Asberg Depression Rating Scale score = 26.6 points [95% CI, 23.0-30.2 points], P < .0005, d' = 4.64). The remission rate for PTSD was 80.0%, and the response rate for TRD was 93.3%. Participants in remission from PTSD after the infusion series (n = 12) had a median time to relapse of 41 days. Similarly, participants whose depression symptoms responded to the infusion series (n = 14) had a median time to relapse of 20 days. Repeated ketamine infusions were associated with transient increases in dissociative symptoms. No participant reported worsening of PTSD symptoms over the study duration.
Conclusions: This study, the first open-label study of repeated ketamine infusions in a comorbid population, found rapid and sustained improvement in PTSD and depression symptoms. This report suggests that repeated ketamine treatments are safe and may represent an efficacious treatment for individuals with comorbid PTSD and TRD.
Trial registration: ClinicalTrials.gov identifier: NCT02577250.
© Copyright 2018 Physicians Postgraduate Press, Inc.
Similar articles
-
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.J Clin Psychiatry. 2015 Mar;76(3):247-52. doi: 10.4088/JCP.13m08852. J Clin Psychiatry. 2015. PMID: 25271445
-
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.JAMA Psychiatry. 2014 Jun;71(6):681-8. doi: 10.1001/jamapsychiatry.2014.62. JAMA Psychiatry. 2014. PMID: 24740528 Clinical Trial.
-
Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.Am J Psychiatry. 2019 May 1;176(5):401-409. doi: 10.1176/appi.ajp.2018.18070834. Epub 2019 Mar 29. Am J Psychiatry. 2019. PMID: 30922101 Clinical Trial.
-
Ketamine as an alternative treatment for treatment-resistant depression.Perspect Psychiatr Care. 2013 Jan;49(1):2-4. doi: 10.1111/ppc.12006. Epub 2012 Dec 30. Perspect Psychiatr Care. 2013. PMID: 23293991 Review. No abstract available.
-
Intravenous ketamine for treatment-resistant major depressive disorder.Ann Pharmacother. 2012 Jan;46(1):117-23. doi: 10.1345/aph.1Q371. Epub 2011 Dec 20. Ann Pharmacother. 2012. PMID: 22190250 Review.
Cited by 22 articles
-
The Multivariate Effect of Ketamine on PTSD: Systematic Review and Meta-Analysis.Front Psychiatry. 2022 Mar 9;13:813103. doi: 10.3389/fpsyt.2022.813103. eCollection 2022. Front Psychiatry. 2022. PMID: 35356723 Free PMC article.
-
Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review.BJPsych Open. 2021 Dec 23;8(1):e19. doi: 10.1192/bjo.2021.1061. BJPsych Open. 2021. PMID: 35048815 Free PMC article. Review.
-
Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial.Neuropsychopharmacology. 2022 Jan 19:1-8. doi: 10.1038/s41386-022-01266-9. Online ahead of print. Neuropsychopharmacology. 2022. PMID: 35046508 Free PMC article.
-
Case Report: Unexpected Remission From Extreme and Enduring Bulimia Nervosa With Repeated Ketamine Assisted Psychotherapy.Front Psychiatry. 2021 Nov 17;12:764112. doi: 10.3389/fpsyt.2021.764112. eCollection 2021. Front Psychiatry. 2021. PMID: 34867548 Free PMC article.
-
Neurophysiological and clinical effects of the NMDA receptor antagonist lanicemine (BHV-5500) in PTSD: A randomized, double-blind, placebo-controlled trial.Depress Anxiety. 2021 Nov;38(11):1108-1119. doi: 10.1002/da.23194. Epub 2021 Jul 12. Depress Anxiety. 2021. PMID: 34254405 Clinical Trial.
Publication types
MeSH terms
Substances
Associated data
Grant support
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical